IKT
Inhibikase Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.67
+3.09%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -39.0%
- EBIT
- -48.9%
- EPS
- +56.0%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +67.9%
- EPS
- +1.1%
Three-year CAGR
- Revenue
- —
- EBITDA
- -93.8%
- EBIT
- -81.8%
- Net income
- -75.4%
- EPS
- +57.8%
- Free cash flow
- -45.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026